{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034271","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.747593+00:00","generated_at":"2026-06-04T11:38:06.861084+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CEO and CFO adopt Rule 10b5-1 trading plans for up to 159,672 shares","bullets":["CEO Yuval Cohen plan: sale of up to 117,066 shares beginning June 13, 2024, ending March 15, 2025.","CFO Sean Moran plan: sale of up to 42,606 shares, same start and termination dates.","Both plans adopted March 15, 2024, disclosed via 8-K on March 20, 2024.","Plans intended to satisfy affirmative defense of Rule 10b5-1(c)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034271","json":"https://secwatch.observer/filing/0000950170-24-034271.json","markdown":"https://secwatch.observer/filing/0000950170-24-034271.md","text":"https://secwatch.observer/filing/0000950170-24-034271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/0000950170-24-034271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/crbp-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:38:06.861084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}